Literature DB >> 33390800

Perspective Adjunctive Therapies for COVID-19: Beyond Antiviral Therapy.

Ping Ho1, Jing-Quan Zheng2,3,4, Chia-Chao Wu5, Yi-Chou Hou6, Wen-Chih Liu7, Chien-Lin Lu8, Cai-Mei Zheng9,10,11, Kuo-Cheng Lu12, You-Chen Chao13,14.   

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is the largest health crisis ever faced worldwide. It has resulted in great health and economic costs because no effective treatment is currently available. Since infected persons vary in presentation from healthy asymptomatic mild symptoms to those who need intensive care support and eventually succumb to the disease, this illness is considered to depend primarily on individual immunity. Demographic distribution and disease severity in several regions of the world vary; therefore, it is believed that natural inherent immunity provided through dietary sources and traditional medicines could play an important role in infection prevention and disease progression. People can boost their immunity to prevent them from infection after COVID-19 exposure and can reduce their inflammatory reactions to protect their organ deterioration in case suffering from the disease. Some drugs with in-situ immunomodulatory and anti-inflammatory activity are also identified as adjunctive therapy in the COVID-19 era. This review discusses the importance of COVID-19 interactions with immune cells and inflammatory cells; and further emphasizes the possible pathways related with traditional herbs, medications and nutritional products. We believe that such pathophysiological pathway approach treatment is rational and important for future development of new therapeutic agents for prevention or cure of COVID-19 infection. © The author(s).

Entities:  

Keywords:  COVID-19; indomethacin; melatonin; statins; traditional medicines; vitamins and minerals

Year:  2021        PMID: 33390800      PMCID: PMC7757136          DOI: 10.7150/ijms.51935

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


  10 in total

Review 1.  Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.

Authors:  Mohitosh Biswas; Nares Sawajan; Thanyada Rungrotmongkol; Kamonpan Sanachai; Maliheh Ershadian; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

2.  Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID-19: A Nationwide Matched Population-Based Cohort Study.

Authors:  Kim Bouillon; Bérangère Baricault; Laura Semenzato; Jérémie Botton; Marion Bertrand; Jérôme Drouin; Rosemary Dray-Spira; Alain Weill; Mahmoud Zureik
Journal:  J Am Heart Assoc       Date:  2022-06-14       Impact factor: 6.106

3.  Indomethacin for refractory COVID or post-COVID headache: a retrospective study.

Authors:  Abouch V Krymchantowski; Raimundo Pereira Silva-Néto; Carla Jevoux; Ana Gabriela Krymchantowski
Journal:  Acta Neurol Belg       Date:  2021-09-21       Impact factor: 2.471

4.  Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between November 2020 and August 2021.

Authors:  Serafino Fazio; Paolo Bellavite; Elisabetta Zanolin; Peter A McCullough; Sergio Pandolfi; Flora Affuso
Journal:  Med Sci Monit       Date:  2021-12-30

5.  Antiviral and cytotoxic effects of a traditional drug KanthaRasaVillai with a cocktail of metallic nanoparticles.

Authors:  Amirtham J A Ranjitsingh; Sandhanasamy Devanesan; Mohamad S AlSalhi; Parameswari Paul; C Padmalatha
Journal:  J King Saud Univ Sci       Date:  2021-11-12

6.  Inflawell® improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial.

Authors:  Sepideh Barzin Tond; Laurent Balenci; Nasim Khajavirad; Mohammadreza Salehi; Abbas Tafakhori; Mohammad Reza Shahmohammadi; Fereshteh Ghiasvand; Sirous Jafari; Sara Abolghasemi; Farzad Mokhtari; Somayyeh Mahmoodi Baram; Tayebe Zarei; Davood Kazemi; Esmaeil Mohammadnejad; Akram Shah-Hosseini; Alireza Haghbin Toutounchi; Soudabeh Fallah; Ali Riazi; Saeed Karima
Journal:  Inflammopharmacology       Date:  2022-02-24       Impact factor: 5.093

7.  A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19.

Authors:  Serafino Fazio; Flora Affuso; Paolo Bellavite
Journal:  Med Sci Monit       Date:  2022-03-08

8.  Applying polypharmacology approach for drug repurposing for SARS-CoV2.

Authors:  Esther Jamir; Himakshi Sarma; Lipsa Priyadarsinee; Selvaraman Nagamani; Kikrusenuo Kiewhuo; Anamika Singh Gaur; Ravindra K Rawal; Natarajan Arul Murugan; Venkatesan Subramanian; G Narahari Sastry
Journal:  J Chem Sci (Bangalore)       Date:  2022-04-22

Review 9.  Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: Time for a suitable proposal.

Authors:  Sergio Pandolfi; Salvatore Chirumbolo; Giovanni Ricevuti; Luigi Valdenassi; Geir Bjørklund; Roman Lysiuk; Monica Daniela Doşa; Larysa Lenchyk; Serafino Fazio
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-12-02       Impact factor: 3.688

Review 10.  Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.

Authors:  Ming-Yieh Peng; Wen-Chih Liu; Jing-Quan Zheng; Chien-Lin Lu; Yi-Chou Hou; Cai-Mei Zheng; Jenn-Yeu Song; Kuo-Cheng Lu; You-Chen Chao
Journal:  Int J Mol Sci       Date:  2021-05-16       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.